-
1Academic Journal
Συγγραφείς: L. A. Burova, P. V. Pigarevsky, V. A. Snegova, N. V. Duplik, Klaas Schalen, Artem A. Totolian, Л. А. Бурова, П. В. Пигаревский, В. А. Снегова, Н. В. Дуплик, Клаас Шален, Артем А. Тотолян
Πηγή: Medical Immunology (Russia); Том 18, № 3 (2016); 221-230 ; Медицинская иммунология; Том 18, № 3 (2016); 221-230 ; 2313-741X ; 1563-0625 ; 10.15789/1563-0625-2016-3
Θεματικοί όροι: экспериментальная модель, IgA-binding streptococci, IgA nephropathy, experimental model, стрептококковая IgAFc-связывающая активность, IgA-нефропатия
Περιγραφή αρχείου: application/pdf
Relation: https://www.mimmun.ru/mimmun/article/view/1034/856; Нефрология (Руководство для врачей) под редакцией И.Е.Тареевой. М.: Медицина, 1995. В 2-х томах. [Nephrology (A guide for physicians in 2 volumes. (Editor I.E.Tareeva)]. Moscow: Meditsina, 1995.; Barratt J., Smith A.C., Feehally J. The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy. Nephrology (Carlton), 2007, Vol. 12, no. 3, pp. 275-284.; Berthelot L., Papista C., Maciel T.T., Biarnes-Pelicot M., Tissandie E., Wang P.H., Tamouza H., Jamin A., Bex-Coudrat J., Gestin A., Boumediene A., Arcos-Fajardo M., England P., Pillebout E., Walker F., Daugas E., Vrtosvnik F., Flamant M., Benhamou M., Cogné M., Moura I.C., Monteiro R.C. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J. Exp. Med., 2012, Vol. 209, no. 4, pp. 793-806.; Berthelot L., Monteiro R.C. Formation of IgA deposits in Berger’s disease: what we learned from animal models. Biol. Aujourd’hui, 2013, Vol. 207, no. 4, pp. 241-247.; Boyd J.K., Cheung C.K, Molyneux K., Feehally J., Barratt J. An update on the pathogenesis and treatment of IgA nephropathy. Kidney International, 2012, Vol. 81, pp. 833-843.; Burova L., Thern A., Pigarevsky P., Seliverstova V., Gavrilova E., Nagornev V., Schalen C., Totolian A. Role of group A streptococcal IgG-binding protein in triggering experimental glomerulonephritis in the rabbit. APMIS, 2003, Vol. 111, pp. 955-962.; Burova L., Pigarevsky P., Seliverstova V., Gupalova T., Schalen C., Totolian A. Experimental poststreptococcal glomerulonephritis elicited by IgGFc-binding M family proteins and blocked by IgG Fc fragment. APMIS, 2012, Vol. 120, no. 3, pp. 221-230.; Collan Y. Morphometry in pathology: another look at diagnostic histopathology. Pathol. Res. Pract., 1984, Vol. 1, pp. 189-192.; Coppo R. The pathogenetic potential of environmental antigens in IgA nephropathy. Am. J. Kidney Dis., 1988, Vol. 12, no. 5, pp. 420-424.; Coppo R. The intestine-renal connection in IgA nephropathy. Nephrol. Dial. Transplant., 2015, Vol. 30, no. 3, pp. 360-366.; Hashimoto A., Suzuki Y., Suzuki H., Ohsawa I., Brown R., Hall S., Tanaka Y., Novak J., Ohi H., Tomino H. Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes. Am. J. Pathol., 2012, Vol. 181, no. 4, pp. 1338-1347.; Jessen R.H., Emancipator S.N., Jacobs G.H., Nedrud J.G. Experimental IgA-IgG nephropathy induced by a viral respiratory pathogen. Dependence on antigen form and immune status. Lab. Invest., 1992, Vol. 67, no. 3, pp. 379-386.; Kovalenko P., Fujinaka H., Yoshida Y., Kawamura H., Qu Z., El-Shemi A., Li H., Matsuki A., Bilim V., Yaoita E., Abo T., Uchiyama M., Yamamoto T. Fc receptor-mediated accumulation of macrophages in crescentic glomerulonephritis induced by antiglomerular basement membrane antibody administration in WKY rats. International Immunology, 2004, Vol. 16, no. 5, pp. 625-634.; Liu H., Peng Y., Liu F., Xiao W., Zhang Y., Li W. Expression of IgA class switching gene in tonsillar mononuclear cells in patients with IgA nephropathy. Inflamm Res., 2011, Vol. 60, no. 9, pp. 869-878.; Meng H., Ohtake H., Ishida A., Ohta N., Kakehata S., Yamakawa M. IgA production and tonsillar focal infection in IgA nephropathy. J. Clin. Exp. Hematop., 2012, Vol. 52, no. 3, pp. 161-170.; Nakata J., Suzuki Y., Suzuki H., Sato D., Kano T., Yanagawa H., Matsuzaki K., Horikoshi S., Novak J., Tomino Y. Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. PloS One, 2014, Vol. 9, no. 2, e89707.; Okazaki K., Suzuki Y., Otsuji M., Suzuki H., Kihara M., Kajiyama T., Hashimoto A., Nishimura H., Brown R., Hall S., Novak J., Izui S., Hirose S., Tomino Y. Development of a model of early-onset IgA nephropathy. J. Am. Soc. Nephrol., 2012, Vol. 23, no. 8, pp. 1364-1374.; Piccolo M., De Angelis M., Lauriero G., Montemurno E., Di Cagno R., Gobbetti M. Salivary Microbiota associated with immunoglobulin A. Nephropathy. Microb. Ecol., 2015, Vol. 70, no. 2, pp. 557-565.; Schmitt R., Carlsson F., Mörgelin M., Tati R., Lindahl G., Karpman D. Tissue deposits of IgA-binding streptococcal M proteins in IgA nephropathy and Henoch-Schonlein purpura. Am. J. Pathol., 2010, Vol. 176, no. 2, pp. 608-618.; Schmitt R., Ståhl A., Olin A., Kristoffersson A.-C., Rebetz A., Novak J., Lindahl G., Karpman D. The combined role of galactose-deficient IgA1 and Streptococcal IgA-binding M protein in inducing IL-6 and C3 secretion from human mesangial cells: Implications for IgA nephropathy. J. Immunol., 2014, Vol. 193, no. 1, pp. 317-326.; Stenberg L., O’Toole P., Lindahl G. Many group A streptococcal strains express two different immunoglobulin-binding proteins, encoded by closely linked genes: characterization of the proteins expressed by four strains of different M-type. Molecular Microbiology, 1992, Vol. 6, no. 9, pp. 1185- 1194.; Suzuki H., Run Fan, Zhixin Zhang, Brown R., Hall S., Bruce A.J., Chatham W.W., Suzuki Y., Wyatt R.J.; Moldoveanu Z., Lee J.Y., Robinson J., Tomana M., Tomino Y., Mestecky J., Novak J. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J. Clin. Invest., 2009, Vol. 119, no. 6, pp. 1668-1677.; Suzuki H., Kiryluk K., Novak J., Moldoveanu Z., Herr A.B., Renfrow M.B., Wyatt R.J., Scolari F., Mestecky J., Gharavi A.G., Bruce A.J. The pathophysiology of IgA nephropathy. J. Am. Soc. Nephrol., 2011, Vol. 22, pp. 1795-1803.; Suzuki H., Suzuki Y., Novak J., Tomino Y. Development of animal models of human IgA nephropathy. Drug Discov. Today Dis. Models, 2014, Vol. 11, pp. 5-11.; Tanaka M., Seki G., Someya T., Nagata M., Fujita T. Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy. Clin. Dev. Immunol., 2011, Vol. 2011, ID 470803.; Tian J., Wang Y., Zhou X., Li Y., Wang C., Li J., Li R. Rapamycin slows IgA nephropathy progression in the rat. Am. J. Nephrol., 2014, Vol 39. no. 3, pp. 218-229.; Tomana M., Matousovic K., Julian B.A., Radl J., Konecny K., Mestecky J. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int., 1997, Vol. 52, no. 2, pp. 509-516.; Wyatt R.J., Bruce A.J. IgA Nephropathy. N. Engl. J. Med., 2013, Vol. 368, pp. 202-214.; https://www.mimmun.ru/mimmun/article/view/1034